Manufacturers of Alzheimer’s disease drugs have identified blood tests as a way to accelerate diagnosis and treatment.

The most recent lawsuit is from winter 2024, when the California attorney general announced a $5 million settlement with ...

Nearly a year after Labcorp struck a deal for certain diagnostics assets from BioReference Health, the lab-testing giant is back to buy the firm’s cancer tests. Labcorp is paying $192.5 million ...

Labcorp has reached an agreement to acquire BioReference Health's oncology diagnostic testing assets for up to $225 million upon closure of the transaction. The deal is expected to close in the ...

Looking ahead, industry tailwinds include the expansion of personalized medicine, increased adoption of at-home and rapid ... With over 600 million tests performed annually and involvement in 90% of ...

Labcorp (LH) announced the nationwide launch of its pTau-217/Beta Amyloid 42 Ratio, a powerful new blood-based biomarker test to aid in the ...

BioReference Health, a biotech company, is laying off 81 employees at its main laboratory in Elmwood Park. The move comes ...

Labcorp is now offering a blood-based biomarker test in the U.S. to support the diagnosis of Alzheimer's disease. The immunoassay measures the ratio of ptau-217 and beta amyloid 42, two distinct ...

Looking ahead, industry tailwinds include the expansion of personalized medicine, increased adoption of at-home ... tests performed annually and involvement in 90% of FDA-approved drugs in 2023 ...